These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33508529)

  • 1. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.
    Ma C; Zhang Q; Greten TF
    Cell Immunol; 2021 Mar; 361():104295. PubMed ID: 33508529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles.
    Bayik D; Lauko AJ; Roversi GA; Serbinowski E; Acevedo-Moreno LA; Lanigan C; Orujov M; Lo A; Alban TJ; Kim A; Silver DJ; Nagy LE; Brown JM; Allende DS; Aucejo FN; Lathia JD
    Sci Rep; 2020 Nov; 10(1):18848. PubMed ID: 33139767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid-derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications.
    Yue Y; Ren Z; Wang Y; Liu Y; Yang X; Wang T; Bai Y; Zhou H; Chen Q; Li S; Zhang Y
    Immun Inflamm Dis; 2024 Sep; 12(9):e70007. PubMed ID: 39222024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.
    Kalathil SG; Thanavala Y
    Cell Immunol; 2021 Mar; 361():104280. PubMed ID: 33445053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially.
    Zhao W; Xu Y; Xu J; Wu D; Zhao B; Yin Z; Wang X
    Int Immunopharmacol; 2015 Jun; 26(2):314-21. PubMed ID: 25891236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
    Wang D; An G; Xie S; Yao Y; Feng G
    Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
    Xu M; Zhao Z; Song J; Lan X; Lu S; Chen M; Wang Z; Chen W; Fan X; Wu F; Chen L; Tu J; Ji J
    Exp Cell Res; 2017 Feb; 351(2):142-149. PubMed ID: 28109867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives.
    Rajkumari S; Singh J; Agrawal U; Agrawal S
    Int Immunopharmacol; 2024 Dec; 142(Pt A):112949. PubMed ID: 39236460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
    Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
    Front Immunol; 2020; 11():613215. PubMed ID: 33679700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic myeloid-derived suppressor cells in cancer.
    Medina-Echeverz J; Eggert T; Han M; Greten TF
    Cancer Immunol Immunother; 2015 Aug; 64(8):931-40. PubMed ID: 26133122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
    De Cicco P; Ercolano G; Ianaro A
    Front Immunol; 2020; 11():1680. PubMed ID: 32849585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunobiology of myeloid-derived suppressor cells in cancer.
    Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M
    Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-activated liver stromal cells regulate myeloid-derived suppressor cells accumulation in the liver.
    Zhang H; He G; Kong Y; Chen Y; Wang B; Sun X; Jia B; Xie X; Wang X; Chen D; Wei L; Zhang M; Zeng H; Chen H
    Clin Exp Immunol; 2017 Apr; 188(1):96-108. PubMed ID: 28019655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans-retinoic acid inhibits hepatocellular carcinoma progression by targeting myeloid-derived suppressor cells and inhibiting angiogenesis.
    Li X; Luo X; Chen S; Chen J; Deng X; Zhong J; Wu H; Huang X; Wang C
    Int Immunopharmacol; 2023 Aug; 121():110413. PubMed ID: 37301119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.